Amneal Pharmaceuticals Hits New 52-Week High of $16.34

Amneal Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 16.34 on June 11, 2026. This achievement highlights the company's strong performance in the pharmaceuticals and biotechnology sector, particularly impressive given its small-cap market status with a valuation of USD 3,728 million. Over the past year, Amneal Pharmaceuticals has demonstrated remarkable growth, with a performance increase of 138.54%, significantly outpacing the S&P 500's 22.78% gain during the same period. The company's price-to-earnings (P/E) ratio stands at 22.00, indicating its valuation relative to earnings, while its price-to-book ratio is reported at -52.66. Despite a dividend yield of 0.00% and a notable debt-to-equity ratio of -32.15, the stock's recent performance reflects a robust market position. The 52-week low for Amneal Pharmaceuticals was recorded at USD 7.67, further emphasizing the stock's upward trajectory. This milestone marks a pivotal moment for the company as it continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry.